CSAAI 2022 A Midsummer Night's Wheeze
It is an exciting time in the field of allergy and immunology. This CME program is designed to allow attendees to continue exploring the field. Covered topics include oral food challenges and novel food allergy therapies, contact dermatitis, asthma and biologics, and more!
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and California Society of Allergy, Asthma & Immunology (CSAAI). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity
CBRN
The American College of Allergy, Asthma & Immunology (ACAAI) is a provider, approved by the California Board of Registered Nursing, Provider Number CEP17239, for 10.5 contact hours.
Commercial Support
This activity is supported in part by independent medical education grants from Stallergenes Greer, CSL Behring and BioCryst.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity the participant should be able to:
At the conclusion of this activity, participants should be able to:
• Describe signaling pathways and their clinical implications in atopic dermatitis
• Outline an endotype, phenotype and guideline-based approach to the treatment of asthma
• Discuss strategies to overcome COVID-19 vaccine misinformation and hesitancy
• Diagnose and manage eosinophilic gastrointestinal disorders
• Diagnose and manage non IgE-mediated drug allergy
• Diagnose and manage hereditary angioedema
• Diagnose and manage chronic urticaria
• Discuss current and future allergy immunotherapy treatment options for respiratory
allergies
• Outline an approach to the use of biologics for allergic diseases, including asthma, chronic
urticaria and atopic dermatitis
• Evaluate for potential immunodeficiency
• Discuss the “long COVID-19 syndrome”
All identified relevant financial relationships have been mitigated.
Jonathan Bernstein, MD - Speaker
Advisor: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Allakos
Speaker: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Optinose
Independent contractor: AstraZeneca, Sanofi Regeneron, Novartis, Genentech, CSL Behring, Takeda/Shire, BioCryst, Pharming, GSK, Allakos
J. Andrew Bird, MD - Speaker
Independent contractor: DBV Technologies, Aimmune
Consultant: DBV Technologies
Luz Fonacier, MD - Speaker
Advisor: Pfizer, AbbVie, Lilly
Independent contractor: Pfizer
Madeleine Ramos, MD – Planner
Advisor: Regeneron
Barbara Ariue, MD – Moderator, Planner
Consultant: Regeneron
Raffi Tachdjian, MD – Planner
Speaker: Takeda, CSL Behring, Pharming, BioCryst, Sanofi, GSK, Amgen
Independent contractor: Takeda, CSL Behring, Pharming, BioCryst
Sonal R. Patel, MD – Planner
Speaker: Sanofi/Regeneron
The following have no relevant financial relationships to disclose:
Kimberly G. Blumenthal, MD - Speaker
Warner Carr, MD - Speaker
Anil Nanda, MD - Speaker
Cindy Nguyen, DO - Speaker
Kevin Pedrotti - Speaker
Nina Sadigh, MD - Speaker
LanAnh Do, MD – Moderator, Planner
Marilyn Li, MD – Moderator, Planner
Vincent Tubioli, MD – Planner
Steven Meltzer, MD – Planner
Javed Sheikh, MD – Planner
Myngoc Nguyen, MD – Planner
Karol Anderson – Planner
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (CSAAI). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 10.50 AMA PRA Category 1 Credit™
- 10.50 Attendance
- 10.50 CBRN